Prediabetes in patients treated with antipsychotic drugs

Journal of Clinical Psychiatry

Volumn 73, Issue 4, 2012, Pages 460-466

  Manu, Peter ^a,b   Correll, Christoph U ^a,b,c   Van Winkel, Ruud ^d,e   Wampers, Martien ^d   De Hert, Marc ^d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

EID: 84860553031     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06822     Document Type: Article

References (37)

1. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care. 2010;33(suppl 1):S11-S61. doi:10.237/dc10-S01 PubMed
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183-1197. PubMed
3. Genuth S, Alberti KG, Bennett P, et al Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160-3167. doi:10.237/diacare.26. 1.3160 PubMed
4. Rhee MK, Herrick K, Ziemer DC, et al. Many Americans have prediabetes and should be considered for metformin therapy. Diabetes Care. 2010;33(1):49-54. doi:10.237/dc09-0341 PubMed
5. Zhou X, Pang Z, Gao W, et al. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. Diabetes Care. 2010;33(3):545-550. doi:10.237/dc09-1410 PubMed
6. Mostafa SA, Khunti K, Srinivasan BT, et al. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Res Clin Pract. 2010;90(1):100-108. doi:10.1016/j.diabres.2010.06.08 PubMed
7. Karve A, Hayward RA. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic US adults. Diabetes Care. 2010;33(11):2355-2359. doi:10.237/dc09-1957 PubMed
8. Lipska KJ, De Rekeneire N, Van Ness PH, et al. Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c. J Clin Endocrinol Metab. 2010;95(12):5289-5295. doi:10.1210/jc.2010-171 PubMed
9. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93. doi:10.2165/023210-2051901-01 PubMed (Pubitemid 40677047)
10. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry. 2006;18(3):183-194. doi:10.1080/1040123060801234 PubMed (Pubitemid 44576440)
11. Smith M, Hopkins D, Peveler RC, et al. First- v second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406-411. doi:10.192/bjp.bp.107. 037184 PubMed (Pubitemid 351809892)
12. Yood MU, DeLorenze G, Quesenberry CP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent - results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf. 2009;18(9):791-799. doi:10.102/pds.1781 PubMed
13. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2008;69(3):472-479. doi:10.408/JCP.v69n0320 PubMed (Pubitemid 351549403)
14. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997-2004. doi:10.1038/np.2010.78 PubMed
15. Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4):266-271. doi:10.192/bjp.bp.109.076935 PubMed
16. Correll CU, Kane JM, Manu P. Identification of high-risk coronary heart disease patients receiving atypical antipsychotics: single lowdensity lipoprotein cholesterol threshold or complex national standard? J Clin Psychiatry. 2008;69(4):578-583. doi:10.408/JCP.v69n0409 PubMed (Pubitemid 351792332)
17. Duncan EJ, Woolson SL, Hamer RM, et al. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol. 2009;24(4):204-213. doi:10.1097/YIC. 0b013e32832d6c18 PubMed
18. Osuntokun OO, Millen B, Xu WI, et al. Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. J Psychopharmacol. 2011;25(5):630-638. PubMed
19. Bond DJ, Kauer-Sant'Anna M, Lam RW, et al. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). J Affect Disord. 2010;124(1-2):108-117. doi:10.1016/j.jad.209.10.023 PubMed
20. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1-3):91-100. doi:10.1016/j.schres.206.08.017 PubMed (Pubitemid 44881290)
21. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health. 2006;2(1):14. doi:10.186/1745-0179-2-14 PubMed
22. Correll CU, Frederickson AM, Kane JM, et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with secondgeneration antipsychotic drugs. J Clin Psychiatry. 2006;67(4):575-583. doi:10.408/JCP. v67n0408 PubMed (Pubitemid 43764234)
23. Correll CU, Frederickson AM, Kane JM, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10(7):788-797. doi:10.1/j.139-5618.208.0625.x PubMed
24. Aas IH. Guidelines for rating Global Assessment of Functioning (GAF). Ann Gen Psychiatry. 2011;10(1):2. doi:10.186/174-859X-10-2 PubMed
25. Rabinowitz J, Mehnert A, Eerdekens M. To what extent do the PANSS and CGI-S overlap? J Clin Psychopharmacol. 2006;26(3):303-307. doi:10.1097/01.jcp. 0218407.10362.6e PubMed (Pubitemid 43804622)
26. Grundy SM, Brewer HB Jr, Cleeman JI, et al National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109(3):433-438. doi:10.161/01.CIR.01245.75752.C6 PubMed (Pubitemid 38133916)
27. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272. doi:10.408/JCP.v65n0219 PubMed
28. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773. doi:10.101/jama.209.1549 PubMed
29. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12(2):116-141. doi:10.1/j.139-5618.2010.0798.x PubMed
30. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97-107. doi:10.1016/j.molmed.2010.10.010 PubMed
31. Nathan DM, Davidson MB, DeFronzo RA, et al American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753-759. doi:10.237/dc07-920 PubMed (Pubitemid 46354366)
32. American College of Endocrinology Task Force on Pre-Diabetes. American College of Endocrinology Consensus Statement on the Diagnosis and Management of Pre-Diabetes in the Continuum of Hyperglycemia: When Do the Risks of Diabetes Begin. Washington, DC: American College of Endocrinology Task Force on Pre-Diabetes; 2008.
33. Knowler WC, Barrett-Connor E, Fowler SE, et al Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512 PubMed (Pubitemid 34437694)
34. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35(7):1520-1530. doi:10.1038/np.2010.21 PubMed
35. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119(3):171-179. doi:10.1/j.160-047.208.0134.x PubMed
36. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry. 2010;67(1):17-24. doi:10.101/archgenpsychiatry.209.179 PubMed
37. Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother. 2010;10(7):1175-1200. doi:10.1586/ern.10.85 PubMed